AstraZeneca’s (AZN) Sell Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reissued their sell rating on shares of AstraZeneca (LON:AZN) in a research note released on Tuesday,Digital Look reports. The brokerage currently has a £115 price target on the biopharmaceutical company’s stock.

Several other equities research analysts also recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a £180 target price on shares of AstraZeneca in a report on Friday, June 26th. Citigroup lifted their price target on AstraZeneca from £175 to £178 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Berenberg Bank reaffirmed a “buy” rating and set a £160 price objective on shares of AstraZeneca in a research note on Tuesday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus target price of £153.

AstraZeneca Stock Performance

AZN opened at £127.20 on Tuesday. The firm has a market cap of £197.27 billion, a PE ratio of 19.16, a P/E/G ratio of 0.86 and a beta of 0.23. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 64.10. The business has a fifty day simple moving average of £134.30 and a 200-day simple moving average of £140.33. AstraZeneca has a fifty-two week low of £107.84 and a fifty-two week high of £157.32.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.